Ranking Profile - Arvinas Inc

Introduction

Arvinas Inc (Arvinas) is a biopharmaceutical company that develops protein degradation therapeutics. The company develops novel therapeutics for the treatment of neuroscience, oncology, and other therapeutic areas. Its pipeline product includes ARV-471 for breast cancer, bavdegalutamide (ARV-110) for prostate cancer, and ARV-766 for the treatment of men with mCRPC. Arvinas’s protein degradation technology platform PROTAC Discovery Engine develops proteolysis-targeting chimera, or PROTAC-targeted protein degraders, and addresses a broad range of intracellular disease targets. The company intends to expand its transformative protein degradation technology and its product candidates into clinical development through collaborations with pharmaceutical companies. Arnivas is headquartered in New Haven, Connecticut, the US.